Biotechnology - Rare diseases, Oncology


Current filters:

Rare diseasesOncology

Popular Filters

bluebird bio poised to advance gene therapy pipeline

bluebird bio poised to advance gene therapy pipeline


US clinical-stage biotech firm bluebird bio is advancing a pipeline focused on gene therapy, a rapidly…

Biotechnologybluebird bioCelgene Corp.OncologyRare diseasesResearch

Oncothyreon acquires Alpine Biosciences

Oncothyreon acquires Alpine Biosciences


US biotech firm Oncothyreon says that it has acquired Alpine Biosciences, of Seattle, Washington, a privately…

Alpine BiosciencesBiotechnologyBusiness FinanceImmunotherapyMedicineMergers & AcquisitionsOncologyOncothyreonRare diseasesUSA

US orphan status for Mirati’s mocetinostat and Alexion’s Soliris

US orphan status for Mirati’s mocetinostat and Alexion’s Soliris


USA-based Mirati Therapeutics has been granted Orphan Drug designation by the US Food and Drug Administration…

BiotechnologyOncologyRare diseasesRegulation

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri

Cell Therapeutics reaches price deal with German insurer GKV-SV on Pixuvri


US biotech firm Cell Therapeutics has concluded an agreement with the Germany’s National Association…

BiotechnologyCell TherapeuticsOncologyPixuvriPricingRare diseases

Progenics relaunches registrational trial of Azedra in pheochromocytomas


USA-based Progenics Pharmaceuticals says it is resuming a Phase IIb clinical study of safety and efficacy…

AzedraBiotechnologyOncologyProgenics PharmaceuticalsRare diseasesResearch

SOBI restructures Kineret and Kepivance deals


Swedish Orphan Biovitrum (STO: SOBI) said this morning that it has acquired the full rights to develop…

AmgenAnti-Arthritics/RheumaticsBiotechnologyKepivanceKineretLicensingOncologyPharmaceuticalRare diseasesSwedish Orphan Biovitrum

UK's NICE calls for more data to consider Roche drug for a type of vasculitis


UK drug watchdog the National Institute for Health and Care Excellence (NICE) has today (July 23) published…

BiotechnologyEuropeMabTheraOncologyPharmaceuticalPricingRare diseasesRegulationRoche

Celgene gets negative NICE view on Revlimid in rare blood cancer; presents new data in newly-diagnosed MM


US biotech firm Celgene (Nasdaq: CELG) today (July 11) expressed disappointment at the preliminary decision…

BiotechnologyCelgeneEuropeOncologyPricingRare diseasesRegulationResearchRevlimid

Regulatory news for Hyperion's Ravicti and Seattle Genetics' Adcetris


The US Food and Drug Administration on Friday approved Hyperion Therapeutics' (Nasdaq: HPTX) Ravicti…

AdcetrisBiotechnologyHyperion TherapeuticsNorth AmericaOncologyPatentsPharmaceuticalRare diseasesRavictiRegulationSeattle Genetics

arGEN-X expands antibody deal with Shire; initiates ARGX-110 trial in cancer


Netherlands and Belgium-based preclinical stage biotech firm arGEN-X, specialized in the discovery and…

arGEN-XARGX-110BiotechnologyLicensingOncologyRare diseasesResearchShire

Licensing deals for Amgen/ImmunoGen and Shire/Arrowhead


US biotechnology company ImmunoGen (Nasdaq), which develops anticancer therapeutics using its Targeted…

AmgenArrowhead ResearchBiotechnologyImmunoGenLicensingOncologyPharmaceuticalRare diseasesShire

News briefs: Auxilium/Pfizer accord; Novartis Signifor and RLX030 developments


US specialty drugmaker Auxilium Pharmaceuticals' (Nasdaq: AUXL) shares fell 7.2% to $18.60 at close of…

Auxilium PharmaceuticalsBiotechnologyCardio-vascularLicensingNovartisOncologyPfizerPharmaceuticalRare diseasesResearchRLX030SigniforXiaflexXiapex

Cell Therapeutics initiates launch of Pixuvri in Europe


Following the European approval of the drug this spring (The Pharma Letter May 14), US biotech firm Cell…

BiotechnologyCell TherapeuticsEuropeMarkets & MarketingOncologyPixuvriRare diseases

Cell Therapeutics prepares for Pixuvri launch; posts 2nd-qtr results


US biotech firm Cell Therapeutics (Nasdaq: CTIC) yesterday reported second-quarter 2012 financial results…

BiotechnologyCell TherapeuticsFinancialMarkets & MarketingOncologypacritinibPixuvriRare diseasesResearchtosedostat

CHMP positive on first gene therapy, Glybera; and more opinions


Reversing an earlier negative opinion (The Pharma Letter April 22), the European Medicines Agency's Committee…

AdcetrisBiotechnologyCelgeneDacogenEuropeGlyberaIstodaxJanssen-CilagJohnson & JohnsonOncologyPfizerPharmaceuticalRare diseasesRegulationTakeda PharmaceuticalsuniQureXalkori

News briefs: US priority review for regorafenib; Ph IIb blisibimod data


Bayer HealthCare, a US unit of Germany's Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX)…

Anthera PharmaceuticalsBayerBiotechnologyblisibimodOncologyOnyx PharmaceuticalsPharmaceuticalRare diseasesregorafenibRegulationResearch

Germany's IQWiG finds in favor of Yervoy but not Benlysta or Fampyra


The German Institute for Quality and Efficiency in Health Care (IQWiG) in the past few days issued a…

BenlystaBiogen IdecBiotechnologyBristol-Myers SquibbEuropeFampyraGlaxoSmithKlineNeurologicalOncologyPharmaceuticalPricingRare diseasesRegulationYervoy

Back to top